

SETON HALL | LAW

Healthcare Compliance
Certificate Program



Imelda Álvarez

CEO & Founder

Comply Latam, S.C. (Mexico City)

imelda.alvarez@complylatam.com

Imelda Álvarez has more than 20 years of international **experience** in the field of Integrity and Compliance. Imelda has consulted for **diverse industries** including Healthcare, Technology, Sports, Cybersecurity, Retail, Trade Associations and ONGs. She **chaired** the Latin American Compliance network for the Pharmaceutical and Medical Device Industry (2014-2018). She has been **Advisory Board member** of the Healthcare Compliance Certificate Programs at University of Miami, Seton Hall Law and the Institute of Legal Research of the National Autonomous University of Mexico.

Imelda holds a **law degree** in Mexico City and an **MBA** from the IPADE business school. She accredited the International Certification in Compliance iCECOM by ASCOM (2022), the Latin American Health Care Compliance Certificate Program. Imelda is Certified Auditor for ISO 37001 Antibribery Management Systems and former ISO19600.

Imelda has been **international speaker** since 2012 in specialized forums across the world. She has been part of the faculty in diverse specialized programs at the University of Miami, Seton Hall Law, ADEN Business School, Fifarma, Fedefarma, Cetifarma, IFI and ICC, among others. Her last positions in the corporate world were as Regional Compliance Officer for Latin America and Canada at Novartis and Legal Director and Compliance Officer at Sandoz in Mexico. She has **co-authored in specialized books** on Compliance. Imelda is member of the Strategic Committee at ETHICS, the International Society of Healthcare Ethics and Compliance Professionals (Paris). She has led Comply Academy executive E&C trainings which have had participants from **22 different countries** around the world. Leading Faculty and **co-developer** of the “International Diploma of High Specialty in Ethics, Integrity, Compliance and Bioethics in Health Care”, in collaboration with the Institute of Legal Research (UNAM) and CETIFARMA.